AVADEL PHARMA Stock Analysis (NASDAQ:AVDL)

Add to My Stocks
$9.18 $0.03 (0.33%) AVDL stock closing price Mar 27, 2017 (Closing)
Watch Robo Advisor Video of AVDL Stock Analysis
AVADEL PHARMA
Updated on : Mar 27, 2017
previous close
AVDL 9.2 (0%)
S&P 500 2341.6 (0%)
Closing Price On: Mar 27, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
32.1%
Operating Profit
Operating Margin:
-12.7%
Sector Average:
-1.1%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
1M
Debt/Equity Ratio:
 0.03
Compared to the industry
Cash Flow
Operating cash flow:
-$4.8M
Net Income:
-$22.3M
PROS      CONS
Low Debt Burden
ROE
PS Valuation
Long Term Growth
Operating Margins
ROIC
FCF Margin
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
AVDL PS :
2.5
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-32.4%
Return on Equity:
60.7%
Free Cash Flow Margin:
-15.6%
Double Tap To Exit Full Screen
0:00
/

AVADEL PHARMA Analysis Video

4 5 2

View AVADEL PHARMA stock analysis video. This is our AVDL analyst opinion covering the buy and sell arguments for AVDL stock.

AVADEL PHARMA Stock Rating (3.1/5)

Our AVADEL PHARMA stock opinion is based on fundamentals of the company. This AVADEL PHARMA stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy AVDL stock?

  • With a debt/equity ratio of  0.03, AVADEL PHARMA is comparatively less leveraged than its peers in the Medical sector.
  • The lower PS ratio 2.5 for AVDL stock versus Medical-Drugs industry average of 4.7 is a positive for the company.
  • The LTM ROE of 60.7% for AVADEL PHARMA is attractive.

Should you sell AVDL stock?

  • Revenue growth of 32.1% has been weak over the last 5 years.
  • AVADEL PHARMA registered a negative operating margin of -12.7% (average) over the Trailing Twelve Months (TTM).
  • The lack of profits renders the PE ratio useless for AVDL stock.
  • The company has a negative Return on Invested Capital of -32.4%, which is a red flag.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -15.6%.

Comments on this video and AVADEL PHARMA stock